Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...

If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

First-generation GLP-1 drugs have found to cut down the risk of obesity-related cancers by 41%, outperforming weight-loss ...

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

A new meta-analysis presented at APA 2025 reveals that GLP-1 receptor agonists may help smokers manage post-cessation weight ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...